Funding Round
Nervonik Closes $52.5M Series B for PNS Pain Therapy
Cure Medtech Funding Tracker4/27/2026·04/27/26🌐 USA
Summary
Nervonik closed an oversubscribed $52.5M Series B. Funds will go toward development and commercialization of its peripheral nerve stimulation system for chronic pain.
Why it matters
Nervonik's $52.5M Series B is one of the largest peripheral neuromodulation rounds of 2026, reflecting surging interest in non-opioid pain management. The funding advances their PNS platform toward pivotal trials as payers increasingly cover neuromodulation over long-term opioid prescriptions.
#BCI#Industry#Neurostimulation#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in